Programm                 "Degeneration und Regeneration– Grundlagen, Diagnostik und Therapie"


Hotelbuchung
   Hotel Registration
Grußwort
   Welcome address
Beteiligte Gesellschaften
   Societies involved
DOG Information
   DOG Information
Eröffnung des Kongresses
   Opening Ceremony
Preise
   Awards
Ablauf der Tagung 2003
   General overview of congress
Lageplan der Räumlichkeiten
   Map of Congress Center
Wissenschaftliche Themen
   Scientific topics
Symposien
   Symposia
Wissenschaftliches Programm
   Scientific program
Posterpräsentationen
   Poster Presentation
Kurse
   Courses
Begleitende Veranstaltungen
   Accompanying program
Arbeitssitzungen
   Working sessions
Rahmenprogramm
   Social program
Allgemeine Informationen
   General Information
Autorenindex
   Index of Authors
Industrieaussteller
   Commercial exhibitors
Sponsoren
   Sponsors
Impressum



DOG Homepage


Abstract
Abstract

Application of Encapsulated Cell Technology for Treating Ophthalmic Diseases

Tao W.
Neurotech USA, Vice President - Research and Development

Purpose: To develop Encapsulated Cell Technology for the controlled, continuous, and long-term administration of protein drugs in the eye.
Method: Polymer membrane capsules (1.0 cm in length and 1.0 mm in diameter) were loaded with mammalian cells that were genetically engineered to secrete CNTF. The cell containing capsules were then surgically implanted into the posterior chamber of one eye of an rcd1 dog at 7 weeks of age, when retinal degeneration is in progression but not complete. The contralateral eyes were not treated. The capsules remained in the eyes for either 7 weeks or 14 weeks. At the end of the studies, the capsules were explanted and CNTF output and cell viability were evaluated. The eyes were processed for histologic evaluation. To evaluate the pharmacokinetics of long-term delivery of CNTF, the CNTF secreting devices were implanted into the rabbit eyes and the device performance (CNTF output and vitreous CNTF levels) was followed for up to a year.
Results: In the rcd1 dogs, the number of outer nuclei layers (ONL) of photoreceptors was significantly higher in the eye that received a CNTF-secreting implant than the untreated contralateral eye. No adverse effects to the retina in the treated eyes were observed. Furthermore, the long-term pharmacokinetics study demonstrated consistent CNTF delivery in the rabbit eyes for at least one year.
Conclusions: CNTF delivered by encapsulated c


Zurück | Back